SCHEMBL4778161

SCHEMBL4778161

Cc1cncc(-c2cc(C)nc(C(=O)O)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.47
CYP2A6 P11509 3/20 0.39
PIK3CG P48736 1/20 0.39
ATM Q13315 1/20 0.37
MCL1 Q07820 2/20 0.36
KDM4E B2RXH2 1/20 0.36
KMO O15229 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
HIF1A Q16665 1/20 0.36
CYP11B2 P19099 2/20 0.36
CYP11B1 P15538 1/20 0.35
CDK7 P50613 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
CREBBP Q92793 1/20 0.35
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GPR35 Q9HC97 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31031756 0.84 HCAR2 (0.45) HCAR2PIK3CGCYP11B2CYP11B1
SCHEMBL4772383 0.84 HCAR2 (0.45) HCAR2PIK3CGCYP11B2CYP11B1
SCHEMBL4779431 0.83 HCAR2 (0.39) HCAR2ATMMCL1KDM4EKMO
SCHEMBL4772052 0.82 ALOX15 (0.46) HCAR2MCL1KDM4EKMOALOX15
SCHEMBL4772437 0.82 MKNK1 (0.49) PIK3CGMCL1KDM4ECYP11B2CYP11B1
SCHEMBL4777507 0.81 CYP11B2 (0.42) CYP11B2CYP11B1RXRARXRBALDH1A1
SCHEMBL4775974 0.81 CYP11B2 (0.42) PIK3CGCYP11B2CYP11B1
SCHEMBL4778479 0.78 KMO (0.53) CYP2A6KDM4EKMOCYP11B2CYP11B1
SCHEMBL1797769 0.75 NPC1 (0.55) KDM4ESMN1; SMN2
SCHEMBL4779426 0.75 KMO (0.47) MCL1KMOALOX15TSHRHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1987003-A1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-11-05 EP claimed
WO-2007093542-A1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 WO claimed
US-20070197553-A1 4-Aryl-pyridine-2-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2007-08-23 US claimed
EP-1987003-A1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-11-05 EP disclosed
WO-2007093542-A1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 WO disclosed
US-20070197553-A1 4-Aryl-pyridine-2-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197553-A1 4-Aryl-pyridine-2-carboxyamide derivatives GRM2, GRM1, GRM3 HCAR2 55/4885CYP2A6 2071/4885PIK3CG 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.